Navigation Links
The Non-Hodgkin's Lymphoma Drug Market Will Nearly Double to More Than $10 Billion by 2022
Date:10/28/2013

BURLINGTON, Mass., Oct. 28, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, from 2012 to 2022, the launch of five premium-priced new agents—Johnson & Johnson/Janssen/Pharmacyclics' ibrutinib, Gilead Sciences' idelalisib, Roche/Genentech/Chugai/Glycart's obinutuzumab, Celgene's Revlimid and Pfizer's Afinitor—together with the continued use of rituximab (Roche/Genentech/Chugai Seiyaku/Zenyaku Kogyo's Rituxan/MabThera) will fuel more than 6 percent annual growth in the non-Hodgkin's lymphoma (NHL) drug market. In the United States, France, Germany, Italy, Spain, the United Kingdom and Japan, sales will exceed $10 billion in 2022, with the kinase inhibitors ibrutinib and idelalisib comprising more than one-fifth of market share. These two agents will launch as treatments for multiple NHL subpopulations, and their use in combination with existing therapies, as well as monotherapies, will ensure that they will significantly add to the overall size of the market. The anticipated approval of Revlimid in the diffuse large B-cell lymphoma maintenance setting will also trigger significant market growth.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO)

The Pharmacor advisory service entitled Non-Hodgkin's Lymphoma finds that sales of rituximab dominate the current market, and will continue to do so through 2022, regardless of biosimilar rituximab entry. Teva Pharmaceutical Industries' Treanda/Levact/Treakisym/Ribomustin, a cytotoxic chemotherapy that is becoming m
'/>"/>

SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Reduction of Chemotherapy and PET-Guided Radiotherapy in Advanced-Stage Hodgkin Lymphoma: the GHSG HD15 Trial
2. Van Andel Institute Researchers Find Potential Drug Target For Aggressive Form Of Lymphoma
3. The Leukemia & Lymphoma Society and Celator Pharmaceuticals Announce $5 Million Partnership to Support Phase 3 Development of CPX-351 for AML
4. Constellation Pharmaceuticals and The Leukemia & Lymphoma Society Partner to Develop Novel BET Inhibitor for the Treatment of Hematologic Malignancies
5. Burlington Coat Factory Completes Another Record Year of Supporting The Leukemia & Lymphoma Society in its Quest to Beat Cancer
6. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
7. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
8. The Leukemia & Lymphoma Society and Avella Specialty Pharmacy to Present Free Event on Oral Chemotherapy Drugs
9. Ibrutinib Expanded Access Program Open to Eligible U.S. Patients with Relapsed or Refractory Mantle Cell Lymphoma
10. Lilly Announces Enzastaurin Phase III Study Did Not Meet Primary Endpoint in Diffuse Large B-Cell Lymphoma
11. The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... , June 25, 2015 ... ) has announced the addition of the ... and Immunodiagnostics: Global Challenges, Emerging Technologies, Competitive ... 2015 New Frontiers in Clinical Chemistry ... Landscape is a new seven-country strategic analysis ...
(Date:7/2/2015)... CHICAGO, Ill. , July 2, 2015  AbbVie ... financial results on Friday, July 24, 2015, before the ... webcast of the earnings conference call at 8 a.m. ... through AbbVie,s Investor Relations website at www.abbvieinvestor.com . ... after 11 a.m. Central time. About AbbVie ...
(Date:7/2/2015)... ATLANTA , July 2, 2015 Legal-Bay ... U.S. District Judge Joseph Goodwin in the ... (VA) consolidated 26 transvaginal mesh cases against Ethicon for ... nd . The cases for the 26 women include ... by a device made my Johnson & Johnson,s Ethicon ...
Breaking Medicine Technology:New Frontiers in 2015 Global Clinical Chemistry and Immunodiagnostics Market: Challenges, Emerging Technologies, Competitive Landscape 2Judge Sets Single Trial for 26 Ethicon Mesh Cases, says Legal-Bay Lawsuit Settlement Funding 2Judge Sets Single Trial for 26 Ethicon Mesh Cases, says Legal-Bay Lawsuit Settlement Funding 3
... Sept. 9, 2011 Nektar Therapeutics (Nasdaq: ... company,s Phase 2 clinical study of NKTR-102 in patients ... 2011 Breast Cancer Symposium in San Francisco, California.  NKTR-102 ... proprietary polymer conjugate technology, and is being developed in ...
... BRUSSELS, September 9, 2011 The Board of ... that today it agreed to ratify the proposal of the ... legislative package, designed with the help of EFCG and US ... Drug User Fees Act (GDUFA). GDUFA requires the ...
Cached Medicine Technology:Positive Results from Phase 2 Clinical Study of NKTR-102 in Metastatic Breast Cancer Presented in Oral Session at the ASCO 2011 Breast Cancer Symposium 2Positive Results from Phase 2 Clinical Study of NKTR-102 in Metastatic Breast Cancer Presented in Oral Session at the ASCO 2011 Breast Cancer Symposium 3Positive Results from Phase 2 Clinical Study of NKTR-102 in Metastatic Breast Cancer Presented in Oral Session at the ASCO 2011 Breast Cancer Symposium 4Positive Results from Phase 2 Clinical Study of NKTR-102 in Metastatic Breast Cancer Presented in Oral Session at the ASCO 2011 Breast Cancer Symposium 5Positive Results from Phase 2 Clinical Study of NKTR-102 in Metastatic Breast Cancer Presented in Oral Session at the ASCO 2011 Breast Cancer Symposium 6European Fine Chemicals Group Ratifies FDA's Proposed Generic Drug User Fees Act (GDUFA) 2
(Date:7/3/2015)... ... July 03, 2015 , ... Every year, One-to-1 Fitness and the ... provide members of the Red Deer community with free fitness training and indoor fitness ... games, food, events and entertainment raised thousands of charity dollars and ended with a ...
(Date:7/2/2015)... Richmond, VA (PRWEB) , ... July 02, 2015 , ... ... New Albany, Mississippi. The opening is the first sweetFrog store located in Mississippi. The ... fastest growing companies in 2014. , The store, located at 104 Railroad Avenue, New ...
(Date:7/2/2015)... ... July 02, 2015 , ... sweetFrog Enterprises, LLC. is pleased to announce the ... sweetFrog store located in the Lone Star State. The premium frozen yogurt chain was ... , The store, which opened July 1 at Duke’s Travel Plaza, is located at:, ...
(Date:7/2/2015)... ... July 02, 2015 , ... The American ... introduction of the Stop Overdose Stat (S.O.S.) Act of 2015 on June 23, ... this Act seeks to decrease drug overdose – especially of heroin and opioid ...
(Date:7/2/2015)... Lincoln, RI (PRWEB) , ... July 02, 2015 , ... ... keep safety in mind. That’s why Amica Insurance is sharing some tips ... Safety Commission (CPSC), approximately 230 people go to the emergency room daily with fireworks-related ...
Breaking Medicine News(10 mins):Health News:Red Deer Fitness Studio Raises $10,000 for Charity Organization with 24-Hour Train-a-Thon 2Health News:Red Deer Fitness Studio Raises $10,000 for Charity Organization with 24-Hour Train-a-Thon 3Health News:sweetfrog Opens First Location in Mississippi 2Health News:sweetFrog Expands Texas Footprint with Location in Canton 2Health News:AAPCC Supports the Stop Overdose Stat Act of 2015 2Health News:AAPCC Supports the Stop Overdose Stat Act of 2015 3Health News:6 Fireworks Safety Tips from Amica Insurance 2
... ... Free Choice Foundation, an organization of expatriates living in Japan, will exercise ... revision of laws and regulations. They are petitioning for the revision ... April 2010, which will require visa renewal applicants to present proof of ...
... , EDINBURGH, Scotland, September 1 ... has added 25,new staff to its R&D, business development and ... The appointment of key staff is in line with the ... and increasing,its focus on business development and R&D activities. , ...
... A study in the Sept.1 issue of the journal ... of breast cancer patients are impaired during the administration ... of chemotherapy is associated with a temporary disruption of ... progressively worse and more enduring impairments. ...
... , , , NEW ... same music that motivates Madonna? Curious about what "The Remedy" is for ... with a revolutionary approach to having a fit body and a sound ... Sessions offer members the opportunity to download playlists via iTunes from Equinox.com. ...
... ... now reversed decision and will cover patient,s life flight , ... Scottsdale, AZ (PRWEB) August 31, 2009 -- Last year, Sally ... transportation to be evaluated for a liver transplant. Her doctors told her she needed ...
... , , NASHVILLE, Tenn., ... CPIX ) , a specialty pharmaceutical company focused on hospital ... Officer A.J. Kazimi will present at the UBS Global Life ... on Monday, September 21, 2009. Mr. Kazimi will provide an ...
Cached Medicine News:Health News:Free Choice to Petition Japanese Government for Right to Choose Private Health Insurance in Lieu of Japan's Universal Health Care 2Health News:Free Choice to Petition Japanese Government for Right to Choose Private Health Insurance in Lieu of Japan's Universal Health Care 3Health News:Aircraft Reports Material Expansion and Staff Increase 2Health News:Chemotherapy for breast cancer is associated with disruption of sleep-wake rhythm in women 2Health News:Chemotherapy for breast cancer is associated with disruption of sleep-wake rhythm in women 3Health News:Pump Up The Volume: Equinox Releases Exclusive Celebrity Playlists 2Health News:In Final Hour Prior to Litigation, Angel MedFlight's Air Ambulance Team Overturns Decision by Major Insurance Company 2Health News:In Final Hour Prior to Litigation, Angel MedFlight's Air Ambulance Team Overturns Decision by Major Insurance Company 3Health News:Cumberland Pharmaceuticals to Present at UBS Global Life Sciences Conference in New York on September 21, 2009 2
... broad selection of tip styles for ... ophthalmic procedures. Each single use cautery ... safety cap to lock switch in ... in use, and carries a 3-4 ...
... provide a broad selection of tip ... variety of ophthalmic procedures. Each single ... with a safety cap to lock ... when not in use, and carries ...
... broad selection of tip styles for ... ophthalmic procedures. Each single use cautery ... safety cap to lock switch in ... in use, and carries a 3-4 ...
... Probes provide the surgeon with an indirect ... to be easily visualized through the laser ... and light scatter technique, the surgeon can ... flap edge folds, corneal flap striae and ...
Medicine Products: